Travere Therapeutics (TVTX) Tops Q3 EPS by 88c

Travere Therapeutics (NASDAQ: TVTX) reported Q3 EPS of $0.59, $0.88 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $164.9 million versus the consensus estimate of $105.57 million.

For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Robinhood Markets (HOOD) PT Raised to $130 at Cantor Fitzgerald
• Travere Therapeutics (TVTX) PT Raised to $61 at Wedbush